Omadacycline, also known as PTK 0796 and Amadacyclin, is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. Omadacycline is active against strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). The primary effect of omadacycline is on bacterial protein synthesis, inhibiting protein synthesis with a potency greater than that of tetracycline. The binding site for omadacycline is similar to that for tetracycline.
Chung, John Y. L.; Hartner, Frederick W.; Cvetovich, Raymond J. Synthesis development of an aminomethylcycline antibiotic via an electronically tuned acyliminium Friedel-Crafts reaction. Tetrahedron Letters. Volume 49. Issue 42. Pages 6095-6100. Journal. (2008).
Honeyman, Laura; Ismail, Mohamed; Nelson, Mark L.; Bhatia, Beena; Bowser, Todd E.; Chen, Jackson; Mechiche, Rachid; Ohemeng, Kwasi; Verma, Atul K.; Cannon, E. Pat; Macone, Ann; Tanaka, S. Ken; Levy, Stuart. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrobial Agents and Chemotherapy. Volume 59. Issue 11. Pages 7044-7053. Journal; Online Computer File. (2015).
Draper, Michael P.; Tanaka, S. Ken. Minocycline compounds for biodefense. Assignee Paratek Pharmaceuticals, Inc., USA. WO 2016154332. (2016).
